STANS, Switzerland,
May 28, 2021 /PRNewswire/ -- NLS
Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"),
a Swiss clinical-stage pharmaceutical company focused on the
discovery and development of innovative therapies for patients with
rare and complex central nervous system disorders, announces that
Alex Zwyer, Chief Executive Officer
and Co-Founder, is scheduled to present a corporate overview at the
MicroCap Rodeo 2021 Summer Solstice: Best Ideas from the Buyside
Conference, which is being held virtually June 1 – June 4,
2021.
Mr. Zwyer will deliver his corporate presentation on
June 2nd at 8:30am ET (2:30pm
CET), and will be available for one-on-one meetings to be
held throughout the conference.
The presentation will be webcast live and available for replay
at https://www.webcaster4.com/Webcast/Page/2134/41515
The MicroCap Rodeo's third edition is a virtual conference that
brings together the top 35 "best ideas from the buy side".
Qualified institutional investors recommended each of the 35
companies represented as one of their "best ideas". To
receive additional information, request an invitation or to
schedule a one-on-one meeting, please email
angie.goertz@issuerdirect.com.
Investors can register here.
About NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage
biopharmaceutical company led by an experienced management team
with a track record of developing and repurposing product
candidates to treat rare and complex central nervous system
disorders. The Company's lead product candidate,
Quilience® is a proprietary controlled-release
formulation of mazindol (mazindol CR), and is being developed for
the treatment of narcolepsy. Mazindol is a triple monoamine
reuptake inhibitor and partial orexin receptor 2 agonist, which was
used for many years to treat patients diagnosed with narcolepsy in
compassionate use programs. NLS completed a phase 2 study in the
U.S. evaluating mazindol CR in adult subjects with ADHD. The study
met all primary and secondary endpoints and was well-tolerated.
Quilience has received Orphan Drug Designations both in the U.S.
and in Europe for the treatment of narcolepsy.
Corporate Contact
Alex
Zwyer, CEO: +41 41 618 80 00
Investor Relations Contact
Cindy Rizzo: +1 908-229-7050
www.nlspharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/nls-pharmaceutics-to-present-at-the-microcap-rodeo-2021-summer-solstice-best-ideas-from-the-buyside-conference-on-june-1-301301428.html
SOURCE NLS Pharmaceutics Ltd.